Table 2.
Distribution of cleaved parthenotes recorded at different time points after microinjection of siCDC5L into GV oocytes followed by maturation and parthenogenetic activation
Control, without microinjection; NC, microinjected negative control; siCDC5L, microinjected cdc5l siRNAs. a-b and A-B indicate significant differences at p < 0.05 and p < 0.01 levels within the same subcolumns, respectively.
| Group | No. embryos | No. 1-cell | No. 2-cell | No. 3-cell | No. 4-cell | No. 5-cell | |
|---|---|---|---|---|---|---|---|
| % ± S.D. | |||||||
| 20 h | Control | 133 | 78 (58.5 ± 2.0%)A | 53 (39.6 ± 2.7%)A | 1 (1.0 ± 1.6%) | 0 | 0 |
| NC | 132 | 80 (61.0 ± 2.5%)A | 52 (39.0 ± 2.5%)A | 0 | 0 | 0 | |
| siCDC5L | 140 | 107 (76.7 ± 3.7%)B | 33 (23.3 ± 3.7%)B | 0 | 0 | 0 | |
| 26 h | Control | 133 | 36 (27.2 ± 1.6%)a | 73 (54.1 ± 7.3%) | 13 (9.4 ± 3.2%)ab | 5 (4.8 ± 8.2%) | 0 |
| NC | 131 | 39 (31.8 ± 13.1%)ab | 65 (48.2 ± 9.7%) | 21 (15.2 ± 5.3%)a | 2 (2.1 ± 3.6%) | 0 | |
| siCDC5L | 137 | 57 (42.6 ± 5.2%)b | 58 (42.3 ± 0.7%) | 9 (6.1 ± 2.9%)b | 0 | 0 | |
| 39 h | Control | 132 | 15 (12.3 ± 7.4%)A | 29 (21.6 ± 3.9%) | 48 (35.9 ± 3.4%) | 37 (28.2 ± 2.4%)A | 0 |
| NC | 131 | 19 (15.4 ± 6.1%)A | 30 (22.4 ± 3.4%) | 50 (37.3 ± 5.3%) | 30 (23.5 ± 4.0%)A | 0 | |
| siCDC5L | 137 | 51 (38.3 6.1%)B | 37 (27.2 ± 4.9%) | 26 (28.7 ± 4.2%) | 8 (5.9 ± 0.5%)B | 0 | |
| 48 h | Control | 132 | 14 (11.6 ± 7.8%)A | 25 (18.5 ± 3.4%) | 34 (25.3 ± 5.9%) | 56 (42.5 ± 3.7%)A | 0 |
| NC | 131 | 19 (15.4 ± 6.1%)A | 36 (26.0 ± 9.9%) | 24 (18.8% ± 3.1%) | 47 (36.4% ± 3.8%)A | 3 (2.0% ± 2.1) | |
| siCDC5L | 137 | 53 (39.5 ± 6.1%)B | 33 (24.2 ± 5.9%) | 26 (19.2 ± 8.3%) | 12 (8.4 ± 3.8v)B | 0 | |